Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.63 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089 | 0.88 | MIF (0.44) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| Water SCHEMBL14972874 | 0.85 | MIF (0.43) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL22471901 | 0.85 | MIF (0.43) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| Water SCHEMBL29040332 | 0.85 | MIF (0.43) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL19857227 | 0.84 | MIF (0.47) | MIFIDO1LOXL2TAAR1PYCR1 | |
| SCHEMBL27570115 | 0.82 | MIF (0.42) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| Cyclohexane SCHEMBL28302863 | 0.81 | MIF (0.40) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL5466297 | 0.81 | CYP3A4 (0.54) | MIFTRPA1KDM4ECYP3A4TSHR | |
| SCHEMBL31094964 | 0.81 | MIF (0.40) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL24833766 | 0.79 | MIF (0.39) | MIFTRPA1CYP3A4TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | claimed |
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | claimed |
| CN-119301125-A | Crystalline forms of AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2025-01-10 | — | — | CN | claimed |
| WO-2024023666-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | claimed |
| US-10734683-B2 | Additive containing electrolytes for high energy rechargeable metal anode batteries | Viking Power Systems Pte. Ltd. (SG) | 2020-08-04 | — | — | US | claimed |
| EP-3497738-A1 | ADDITIVE CONTAINING ELECTROLYTES FOR HIGH ENERGY RECHARGEABLE METAL ANODE BATTERIES | Pellion Technologies Inc. (US) | 2019-06-19 | — | — | EP | claimed |
| CN-109804487-A | The electrolyte comprising additive for high-energy rechargeable metal anode battery | 派立昂技术公司 | 2019-05-24 | — | — | CN | claimed |
| US-20180048017-A1 | ADDITIVE CONTAINING ELECTROLYTES FOR HIGH ENERGY RECHARGEABLE METAL ANODE BATTERIES | PELLION TECHNOLOGIES, INC. (US) | 2018-02-15 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| WO-2025226892-A1 | SPIROCYCLE-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | disclosed |
| EP-0752991-A1 | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-01-15 | — | — | EP | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
| WO-1995026349-A1 | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1995-10-05 | — | — | WO | disclosed |
| EP-0597088-A1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993014070-A2 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | AKR1C3, AKR1C1, AKR1C2 | MIF 4239/4885IDO1 4279/4885LOXL2 4547/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | MIF 4006/4885IDO1 3249/4885LOXL2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.